NEW YORK, March 18, 2023 /PRNewswire/ — Aquavit Holdings has submitted to FDA an IND for its DTX-024, for the remedy of palmar hyperhidrosis using its patented microchannel technologies™. DTX-024 is a very purified and clinically tested injectable neuromodulator derived from neurotoxins developed by Clostridium botulinum.
Aquavit Logo (PRNewsfoto/Aquavit Pharmaceuticals, Inc.)
Alongside Aquavit’s biosimilar program for its botulinum toxin, this will be the initially in the globe, indicated for palmar hyperhidrosis, authorized by FDA.
Aquavit has been investing in proprietary delivery technologies and linked intellectual house for botulinum toxin. This is a strategic move that puts them ahead of the curve in the fast-building multi-billion-dollar botulinum toxin marketplace.
To proficiently execute the tactic, Aquavit has not as well lengthy ago bolstered its executive group with seasoned veterans from the marketplace and the academia.
Dr. David Crean, PhD, MBA has been named Chief Financial Officer of Aquavit Holdings. He has receive- and sell-side knowledge in mergers & acquisitions (M&A), partnering and investments inside the life sciences and healthcare sectors functioning inside strategic biopharmaceutical companies, private equity, investment banking and venture capital. He commenced his profession inside biopharmaceutical companies a lot far more than 30 years ago, most notably at Allergan, an Abbvie Organization, specifically exactly where he lead deal execution for each and every technologies, option, and enterprise acquisitions and divestitures across a broad selection of therapeutic regions and enterprise units which consists of injectable and topical well being-associated aesthetics, dermatology, neurology, and ophthalmology. He serves on numerous boards which consists of each and every public and private companies and has been awarded really a couple of recognitions which consists of San Diego’s 500 Most Influential persons for the preceding four years (2019 -2022), 2020 Major Believed Leaders by Axial, M&A Advisor of the Year in 2019, and the 2018 Healthcare Hero Award.
Dr. Crean holds FINRA Series 79 and Series 63 licenses and is a Registered Investment Banking Representative of BA Securities LLC, Member FINRA SIPC.
Dr. Churlsu Kwon, MD. PhD. MPH., has been named Chief Healthcare Officer. He is a educated neurosurgeon and neuroscientist who brings a wealth of sensible knowledge and understanding to scientific developments, drug improvement and approval, and new drug discovery. He holds his degrees from University of Oxford and Harvard Healthcare College and at present holds an academic position at Columbia Healthcare College.
With Aquavit’s established track record of establishing and launching worldwide brands, such as AQUAGOLD®, the enterprise has demonstrated their capability to successfully bring revolutionary options to marketplace. With their deep understanding of botulinum toxin and in depth network of physicians, Aquavit is successfully-positioned to make a essential influence in the marketplace.
“The neurotoxin marketplace is expanding immediately, with developing demand for revolutionary options and customized remedy plans. There is at present no FDA approval for palmar hyperhidrosis and by way of our novel route of administration we will be capable to present new solutions to meet the evolving needs of men and women in pathologies that are extremely debilitating. The provision of access for this population is a step in the excellent path towards enhancing their all round well being and successfully-finding. ” Churl-Su Kwon, CMO Aquavit.
Aquavit is an revolutionary healthcare enterprise that provides a substantial selection of proprietary pharmaceutical, biotech and well being-associated device technologies. Aquavit focuses on customized medicine to increase patients’ all round well being, maximize the efficiency of our well being-associated neighborhood, and help the pharmacoeconomics of payers.
View original content material material to download multimedia:https://www.prnewswire.com/news-releases/aquavit-files-added-ind-for-dtx-024-a-new-botulinum-toxin-with-microchannel-technologies-for-palmar-hyperhidrosis-301775589.html
Provide Aquavit Holdings